| Project/Area Number |
23K26797
|
|---|
| Project/Area Number (Other) |
23H02104 (2023)
|
|---|
| Research Category |
Grant-in-Aid for Scientific Research (B)
|
| Allocation Type | Multi-year Fund (2024)
Single-year Grants (2023) |
|---|
| Section | 一般 |
|---|
| Review Section |
Basic Section 37030:Chemical biology-related
|
|---|
| Research Institution | University of Toyama |
|---|
Principal Investigator |
Suresh Awale 富山大学, 学術研究部薬学・和漢系, 准教授 (00377243)
|
|---|
| Co-Investigator(Kenkyū-buntansha) |
藤井 努 富山大学, 学術研究部医学系, 教授 (60566967)
|
|---|
| Project Period (FY) |
2023-04-01 – 2028-03-31
|
| Project Status |
Granted (Fiscal Year 2024)
|
| Budget Amount *help |
¥18,590,000 (Direct Cost: ¥14,300,000、Indirect Cost: ¥4,290,000)
Fiscal Year 2027: ¥3,770,000 (Direct Cost: ¥2,900,000、Indirect Cost: ¥870,000)
Fiscal Year 2026: ¥3,640,000 (Direct Cost: ¥2,800,000、Indirect Cost: ¥840,000)
Fiscal Year 2025: ¥3,640,000 (Direct Cost: ¥2,800,000、Indirect Cost: ¥840,000)
Fiscal Year 2024: ¥3,510,000 (Direct Cost: ¥2,700,000、Indirect Cost: ¥810,000)
Fiscal Year 2023: ¥4,030,000 (Direct Cost: ¥3,100,000、Indirect Cost: ¥930,000)
|
|---|
| Keywords | Pancreatic cancer / antiausterity / napthylisoquinolines / antitumor agents / in vivo / pancreatic cancer / chemical biology / Pancreatic canecer / anti tumor agents |
|---|
| Outline of Research at the Start |
This project aimed to investigate naphthylisoquinoline alkaloids as new anti-tumor chemotherapeutic agents and provide strong preclinical evidence for drug development against pancreatic cancer through in vivo xenograft tests.
|
| Outline of Annual Research Achievements |
We investigated naphthylisoquinoline alkaloids as a potential new chemotherapeutic agent against pancreatic cancer. In 2023, we screened over 200 naphthylisoquinoline alkaloids against MIA PaCa-2 pancreatic cancer cell line and identified promising candidates. Study on structure-activity relationship to guide future development has been achieved. We've also explored the molecular mechanisms of selected compounds, which could lead to a deeper understanding of their anti-cancer effects. In addition, we also discovered novel naphthoquinones as potent antiausterity agents against human PANC-1 pancreatic cancer cells and published the results. Our findings hold promise for the development of novel, targeted treatments for this aggressive disease.
|
| Current Status of Research Progress |
Current Status of Research Progress
2: Research has progressed on the whole more than it was originally planned.
Reason
We've screened a vast library of NIQs, and identified several potent candidates with selective cytotoxicity against pancreatic cancer cells in nutrient-deprived conditions at nanomolar concentration range. We're now investigating the molecular mechanisms of these promising compounds.
|
| Strategy for Future Research Activity |
We'll extensively study the effects of our active NIQ compounds on cancer cell morphology, migration, colony formation, and chemotaxis. We'll also investigate their ability to block survival pathways within the pancreatic tumor microenvironment, aiming to enhance cancer cell death. Finally, we'll evaluate the efficacy of selected NIQs against orthotopic MIA PaCa-2 tumors, both as single agents and in combination with gemcitabine (GEM).
|
